SCHEMBL3575075

SCHEMBL3575075

COc1ccc(-c2cc3c4cc(C#N)ccc4[nH]c3n(C)c2=O)c(OC)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CCNB2 O95067 2/20 0.47
▸ CDK1 P06493 2/20 0.47
▸ CCNB1 P14635 2/20 0.47
▸ GSK3B P49841 2/20 0.47
▸ CDK5 Q00535 2/20 0.47
▸ CDK5R1 Q15078 2/20 0.47
▸ CCNB3 Q8WWL7 2/20 0.47
▸ KDM4E B2RXH2 3/20 0.40
▸ CYP1A2 P05177 1/20 0.40
▸ CYP3A4 P08684 1/20 0.40
▸ CYP1A1 P04798 1/20 0.39
▸ CYP1B1 Q16678 1/20 0.39
▸ EGLN1 Q9GZT9 5/20 0.38
▸ HTR1A P08908 3/20 0.38
▸ HSD17B10 Q99714 2/20 0.38
▸ PKM P14618 2/20 0.38
▸ MAPT P10636 2/20 0.37
▸ NAAA Q02083 1/20 0.37
▸ MEN1 O00255 1/20 0.37
▸ ALDH1A1 P00352 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2386218 0.85 KDM4E (0.43) GSK3BKDM4ECYP1A2CYP3A4HSD17B10
SCHEMBL3570043 0.84 BRD4 (0.43) CCNB2CDK1CCNB1GSK3BCDK5
SCHEMBL3567241 0.82 KDM4E (0.41) GSK3BKDM4ECYP1A2CYP3A4HSD17B10
SCHEMBL3579883 0.82 MEN1 (0.49) CDK5CDK5R1KDM4ECYP1A2CYP3A4
SCHEMBL1340487 0.79 KDM4E (0.43) KDM4EMEN1KMT2AEGFR
SCHEMBL3566184 0.79 MAPT (0.47) KDM4ECYP1A2CYP3A4MAPTMEN1
SCHEMBL3575910 0.78 MAPT (0.49) KDM4ECYP1A2CYP3A4HSD17B10MAPT
SCHEMBL3577091 0.77 KMT2A (0.48) KDM4ECYP3A4MAPTMEN1ALDH1A1
SCHEMBL3571932 0.76 KDR (0.38) KDM4ECYP1A2CYP3A4HSD17B10PKM
SCHEMBL3571934 0.76 KDR (0.38) KDM4ECYP1A2CYP3A4HSD17B10PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7812165-B2 6-substituted pyridoindolone derivatives, production and therapeutic use thereof SANOFI-AVENTIS (FR) 2010-10-12 — — US disclosed
EP-1742947-B1 6-SUBSTITUTED PYRIDOINDOLONE DERIVATIVES PRODUCTION AND THERAPEUTIC USE THEREOF SANOFI AVENTIS (FR) 2008-08-20 — — EP disclosed
US-20070129365-A1 6-Substituted pyridoindolone derivatives, production and therapeutic use thereof SANOFI-AVENTIS (FR) 2007-06-07 — — US disclosed
EP-1742947-A1 6-SUBSTITUTED PYRIDOINDOLONE DERIVATIVES PRODUCTION AND THERAPEUTIC USE THEREOF Sanofi-Aventis (FR) 2007-01-17 — — EP disclosed
WO-2005108398-A1 6-SUBSTITUTED PYRIDOINDOLONE DERIVATIVES PRODUCTION AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2005-11-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070129365-A1 6-Substituted pyridoindolone derivatives, production and therapeutic use thereof PNPO, CYP2D6, DPYD CCNB2 515/4885CDK1 513/4885CCNB1 567/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback